Literature DB >> 10321603

Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid.

J D Heilborn1, M Ståhle-Bäckdahl, F Albertioni, I Vassilaki, C Peterson, E Stephansson.   

Abstract

BACKGROUND: Prednisone alone or in combination with an immunosuppressive drug is usually effective in controlling bullous pemphigoid. However, corticosteroids often cause potentially hazardous side effects, especially in elderly patients.
OBJECTIVE: Our purpose was to evaluate low-dose treatment with methotrexate in elderly patients with generalized bullous pemphigoid.
METHODS: Oral methotrexate, at an initial dosage of 5 mg/wk, was given to 11 consecutive patients older than 70 years of age who were not responding to potent topical steroids. If the response was insufficient, the methotrexate dose was increased by 2.5 mg/wk to a maximum of 12.5 mg/wk.
RESULTS: All patients responded with a marked and rapid decrease in disease activity. The disease was controlled in the majority of patients (8 of 11) with 5 to 7.5 mg of methotrexate per week. Three patients required a weekly dose of 10 to 12.5 mg. At 24 months of follow-up 7 patients were in complete remission and did not require methotrexate.
CONCLUSION: Our study suggests that low-dose oral pulse methotrexate constitutes an effective therapeutic alternative in elderly patients with generalized bullous pemphigoid.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10321603     DOI: 10.1016/s0190-9622(99)70156-8

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Treatment of subepidermal immunobullous diseases.

Authors:  Donna A Culton; Luis A Diaz
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

3.  Methylprednisolone Plus Low-Dose Methotrexate for Bullous Pemphigoid-A Single Center Retrospective Analysis.

Authors:  Agoritsa Gravani; Georgios Gaitanis; Panagiota Spyridonos; Ioannis Alexis; Stelios Tigas; Ioannis D Bassukas
Journal:  J Clin Med       Date:  2022-06-02       Impact factor: 4.964

Review 4.  Autoimmune bullous dermatoses in the elderly: diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Role of methotrexate in the treatment of bullous pemphigoid in the elderly.

Authors:  Timothy Patton; Neil Korman
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 6.  Management of autoimmune skin disorders in the elderly.

Authors:  Wei Jing Loo; Nigel P Burrows
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

7.  Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2010-01-01       Impact factor: 3.923

8.  Therapy of autoimmune bullous diseases.

Authors:  Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

9.  Neutrophils Enable Local and Non-Invasive Liposome Delivery to Inflamed Skeletal Muscle and Ischemic Heart.

Authors:  Junyi Che; Adrian Najer; Anna K Blakney; Paul F McKay; Mohamed Bellahcene; Charles W Winter; Amalia Sintou; Jiaqing Tang; Timothy J Keane; Michael D Schneider; Robin J Shattock; Susanne Sattler; Molly M Stevens
Journal:  Adv Mater       Date:  2020-10-26       Impact factor: 32.086

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.